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Background: Streptococcus pneumoniae is the bacterial agent which most frequently causes pneumonia. In some
Scandinavian countries, this infection is treated with penicillin V since the resistances of pneumococci to this
antibiotic are low. Four reasons justify the undertaking of this study; firstly, the cut-off points which determine
whether a pneumococcus is susceptible or resistant to penicillin have changed in 2008 and according to some
studies published recently the pneumococcal resistances to penicillin in Spain have fallen drastically, with only 0.9%
of the strains being resistant to oral penicillin (minimum inhibitory concentration>2 μg/ml); secondly, there is no
correlation between pneumococcal infection by a strain resistant to penicillin and therapeutic failure in pneumonia;
thirdly, the use of narrow-spectrum antibiotics is urgently needed because of the dearth of new antimicrobials and
the link observed between consumption of broad-spectrum antibiotics and emergence and spread of antibacterial
resistance; and fourthly, no clinical study comparing amoxicillin and penicillin V in pneumonia in adults has been
published. Our aim is to determine whether high-dose penicillin V is as effective as high-dose amoxicillin for the
treatment of uncomplicated community-acquired pneumonia.
Methods: We will perform a parallel group, randomised, double-blind, trial in primary healthcare centres in Spain.
Patients aged 18 to 65 without significant associated comorbidity attending the physician with signs and symptoms
of lower respiratory tract infection and radiological confirmation of the diagnosis of pneumonia will be randomly
assigned to either penicillin V 1.6 million units thrice-daily during 10 days or amoxicillin 1,000 mg thrice-daily during
10 days. The main outcome will be clinical cure at 14 days, defined as absence of fever, resolution or improvement
of cough, improvement of general wellbeing and resolution or reduction of crackles indicating that no other
antimicrobial treatment will be necessary. Any clinical result other than the anterior will be considered as treatment
failure. A total of 210 patients will be recruited to detect a non-inferiority margin of 15% between the two
treatments with a minimum power of 80% considering an alpha error of 2.5% for a unilateral hypothesis and
maximum possible losses of 15%.
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Discussion: This pragmatic trial addresses the long-standing hypothesis that the administration of high doses of a
narrow-spectrum antibiotic (penicillin V) in patients with non-severe pneumonia attended in the community is not less
effective than high doses of amoxicillin (treatment currently recommended) in patients under the age of 65 years.
Trial registration: EudraCT number 2012-003511-63.
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Streptococcus pneumoniae is the bacterial agent which
most frequently causes respiratory tract infections. In-
deed, it is the most common bacteria in acute sinusitis,
acute otitis media and community-acquired pneumonia.
In some European countries, mainly those located in
Northern Europe, pneumonia is treated with penicillin V
since the resistances of these pneumococci to this anti-
biotic are low [1]. In the last years a phenomenon of
greater community prescription of broad-spectrum anti-
biotics has been taking place in many countries, with
amoxicillin-clavulanate and amoxicillin being the antibi-
otics most frequently prescribed by family practitioners
in Spain [2,3]. Antimicrobial resistance may be a cause
of therapeutic failure. It is identified by measuring the
minimum inhibitory concentration (MIC) of the anti-
microbial agent able to inhibit the growth of the micro-
organism. The cut-off points are MICs which define the
infections as susceptible (treatable), with intermediate
resistance (possibly treatable with higher doses) and re-
sistant (not treatable). After re-evaluation taking new
clinical studies into account, in January 2008 the Clinical
and Laboratory Standards Institute published new cut-
offs for penicillin [4]. These new cut-off points were de-
termined on the basis of a series of criteria: first, by the
pharmacokinetic and pharmacodynamic properties of
the antimicrobial agents and second, by the data pub-
lished relating MICs to the clinical outcome of the pa-
tients with pneumococcal infections. With the previous
criteria a pneumococcus was considered to be suscep-
tible with an MIC<0.06 μg/ml, to have intermediate
resistance at between 0.12 and 2 μg/ml and to be resist-
ant when the MIC was >2 μg/ml. At present, the new
cut-off points for patients with meningitis receiving
endovenous penicillin are <2, 4 and >8 μg/ml, respect-
ively, unifying penicillin and amoxicillin. According to
the results of the SAUCE 4 study published in 2010, the
pneumococcal resistances to penicillin in Spain have
fallen drastically, with only 0.9% of the strains being re-
sistant to oral penicillin (MIC>2 μg/ml) [5]. In view of
these results pneumonia could be treated with penicillin
in Spain. In US the American Society of Infectious Dis-
eases also recommends that patients with pneumonia be
treated with penicillin if the causative strain of the infec-
tion is susceptible to this antibiotic [6].Study justification
Four reasons justify the undertaking of this study and
these are: a) as mentioned above the cut-off points
which determine whether a pneumococcus is suscep-
tible or resistant to penicillin have changed; b) there
is no correlation between pneumococcal infection by a
strain resistant to penicillin and therapeutic failure in
pneumonia. Treatment failure has been described in pneu-
monias treated with macrolides and fluoroquinolones.
Curiously however, in contrast with the latter, in a review
of clinical failures due to antimicrobial resistance no cases
of therapeutic failure were reported with β-lactams pre-
scribed at adequate doses [7]. It is important to know
that a large proportion of patients die because of the se-
verity of their disease and the associated comorbidity but
not due to failure of the antibiotic. Thus, the study by
Pallarés et al. has provided evidence that the risk of death
by pneumococcal pneumonia treated with bencilpenicillin
or ampicillin was similar regardless of whether the pa-
tients were infected with germs resistant or not to
penicillin [8]. In other studies evaluating the effective-
ness of penicillin in monotherapy for the treatment of
non-meningeal pneumococcal infections within the
first 48 hours in adults, an increase in mortality was
not observed when the infection was caused by a
strain with an MIC<2 μg/ml [9]. c) It is urgent to re-
turn to the use of reduced spectrum antibiotics. The
increase in the use of broad-spectrum antibacterial
agents has been accompanied by an increase in the
rates of resistances of the microorganisms [10]. More-
over, the incidence of infection by Clostridium diffi-
cile is rising in parallel with an increase in the
prescription of wide spectrum antibiotics [11]. d) No
clinical study comparing amoxicillin and penicillin V
in pneumonia in adults has been published. Amoxi-
cillin is the first-choice option antibiotic for non-
severe community-acquired pneumonia recommended
by the Spanish Society of Family Medicine [12,13],
and also endorsed by other scientific societies, such as
the British Thoracic Society [14], and the European
Respiratory Society/European Society for Clinical Micro-
biology and Infectious Diseases [15]. Although some
clinical trials have compared amoxicillin with penicil-
lin, these were performed in children and with paren-
teral doses [16-19].
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Study hypothesis and objectives
The main hypothesis of this study is that the administra-
tion of high doses of penicillin V in patients with non-
severe pneumonia attended in the community is not less
effective than high doses of amoxicillin (currently
recommended treatment) in patients under the age of
65 years without comorbidities. The main objective of
this phase IV randomised, multicentre, clinical, double-
blind, parallel, clinical trial is to evaluate the efficacy of
phenoxymethylpenicillin (penicillin V) in the antibiotic
treatment of non-severe pneumonia attended in the
community compared with amoxicillin, considering the
rate of clinical cure at 2 weeks. Secondary objectives are
to assess the rate of radiological cure at 4 weeks in the
patients treated with the two antibiotics, evaluate the
rate of clinical cure at 4 weeks in both treatment groups,
and evaluate the presence of adverse effects in the pa-
tients treated with the two antibiotics.
Patient selection
Patients from 18 to 65 years of age without significant as-
sociated comorbidity attending the primary healthcare
centres or emergency departments with signs and symp-
toms of lower respiratory tract infection and radiological
confirmation of the diagnosis of pneumonia will be
recruited in this clinical trial. Exclusion criteria will be
subjects under 18 and over 65 years of age, severe impair-
ment of signs (impairment of consciousness, respiratory
rate > 30 breaths/minute, heart rate > 125 beats/minute,
systolic blood pressure < 90 mm Hg, diastolic blood
pressure < 60 mm Hg, temperature > 40°C, oxygen sat-
uration < 92%), hypersensitivity to β-lactams, important
alteration on chest X-ray, such as alveolar infiltrate in
more than one lobe or bilateral, pleural effusion and/or
pulmonary cavitation, problems to comply with treatment
at home – sociopathy or psychiatric problems, drug and al-
cohol addiction, or within an inadequate family setting –,
lack of tolerance to oral treatment, such as the presence of
nausea and vomiting, gastrectomy, postsurgery and/or
diarrhoea, significant comorbidity including bronchial
asthma, renal failure, hepatic cirrhosis, heart failure,
chronic obstructive pulmonary disease, ischaemic heart
disease, stroke and/or type 1 diabetes mellitus, immuno-
suppression – chronic HIV infection, transplantation, neu-
tropenic, or patients receiving immunosuppressive drugs
or corticosteroids –, terminal disease, pregnancy or lacta-
tion, hospitalisation in the last month, consumption of an-
tibiotics in the last two weeks, difficulty to attend the
programmed visits or refusal to participate in the study.
Randomisation
Patients will be randomly assigned to either penicillin V
1,600,000 units (two 800,000- unit pills) or amoxicillin1,000 mg (two 500-mg pills) both taken thrice daily du-
ring 10 days. Subject numbers will be assigned sequen-
tially as each subject enters the study. The subjects will
be assigned a study drug through a randomisation
schedule based on the randomisation plan. Since this is
a multicentre study a block procedure will be under-
taken for the assignment of each primary care centre
participating in the study. Each container will include 66
pills (60 pills for the treatment plus 6 extra pills). The
study drug, which will be prepared by the Pharmacy
Unit of Hospital Universitari Son Espases (Palma de Ma-
llorca, Spain) and will be labelled with the study number
and a unique identification number.
Use of antithermic drugs or analgesics (acetaminophen,
acetylsalicylic acid or ibuprofen), bronchodilators as well
as any medication, except oral systemic antibiotics, that
the patient is taking and which have been initiated prior
to inclusion in the study will be allowed. Since this is a
clinical study no statistically significant differences are to
be expected in the concomitant treatment administered in
the two treatment arms. In the case of clinical deterior-
ation, the investigating physician will administer another
antibiotic treatment in accordance with the clinical criteria.
Blinding issues
We will perform a double-blind clinical study in which
neither the physician nor the patient will know the treat-
ment administered. The radiologists responsible for
diagnosing pneumonia and confirming the radiological
cure will be also blind to the clinical data and the treat-
ment administered. The two medications will be presen-
ted as the same type of capsule. This will ensure that
even on opening the container no one will know which
medication has been given.
Withdrawal
Each participant will have the right to withdraw from
the study at any time. In addition, the investigator may
discontinue a participant from the study at any time if
the investigator considers it necessary for any reason
including significant protocol deviation, significant non-
compliance with the treatment regimen or study re-
quirements (the patient will be required to return all the
medication samples not taken to the investigator; if the
remaining medication is not returned, compliance will
be evaluated as insufficient), an adverse event which re-
quires discontinuation of the study medication or results
in inability to continue to comply with study procedures,
disease progression which requires discontinuation of
the study medication or results in inability to continue
to comply with study procedures. In cases of clinical
deterioration the medical investigator will implement
another antibiotic treatment considering the clinical cri-
teria, withdrawal of consent or loss to follow up.
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The variable of the main result will be clinical cure at
14 days, defined as absence of fever, resolution or im-
provement of cough, improvement of general wellbeing
and normal respiratory auscultation or reduction of cra-
ckles indicating that no other antimicrobial treatment is
necessary. Any clinical result other than the anterior will
be considered as treatment failure. Variables of second-
ary results will be efficacy at day 30 after the initiation of
antibiotic treatment, radiological resolution or improve-
ment one month after the initiation of the treatment,
complete clinical resolution at day 14 defined as the
total resolution of acute symptoms and signs related to
the infection, the presence of adverse events which may
appear during the treatment, and compliance with treat-
ment administered. The radiologists responsible for
diagnosing pneumonia and confirming the radiological
cure will be blind to the clinical data and the treatment
administered.
Ascertainment of visits
On fulfilling the inclusion criteria the nature of the study
will be explained to the patient and informed consent
will be requested. All the eligible patients should have a
chest X-ray (posteroanterior and lateral projection) de-
monstrating pneumonic infection. The study scheme
and the visit program will be explained to the patient
(Table 1). The patients will be randomised to one of the
2 treatment groups and the medication given. The first
dose of the drug will be administered in the presence of
the investigator. They will be dispensed the drugs for ten
days.
At the first follow-up visit, scheduled at day 3, a worsen-
ing of the clinical situation of the patient will be evaluated
to determine whether a change in the antibiotic treatment
is necessary. Likewise, compliance and possible secondary
effects of the treatment will be evaluated. At the second
follow-up visit, at day 14, the clinical evolution of the signs
and symptoms will be evaluated and the need to change
the antibiotic treatment in the case of worsening in theTable 1 Variables to be collected during the clinical trial
Visit 1 Visit 2 Visit 3 Visit 4
Day 0 Day 3 Day 14 Day 30
Medical history and examination x x x x
Pulse oximeter determination x x x x
Chest X-ray x x
Informed consent form x
Randomisation x
Evaluation of clinical evolution x x x
Assessment of adverse events x x x
Review of compliance x xclinical manifestations will be determined. Likewise, com-
pliance and possible secondary effects of the treatment
will be evaluated. The last follow-up visit, scheduled at
day 30, the clinical outcome of the signs and symptoms of
the pneumonia will be evaluated and a new chest X-ray
will be performed (posteroanterior and lateral projection)
to confirm radiological resolution of the pneumonia. The
medication will be discontinued in the case of clinical fail-
ure in follow-up visits 2 and 3 or in the case of significant
adverse events.
The variables will be registered in an electronic case
report form designed by the Hospital Universitari Vall
d’Hebron (Barcelona, Spain). The variables considered in
this trial will be sociodemographic (birth date, gender,
race) and toxic habits (smoking and drinking beha-
viours), present medical history (presence and duration
of signs and symptoms: fever, cough, expectoration, spu-
tum purulence, diarrhoea, malaise, muscular aches, joint
aches, thoracic pain, dyspnoea, respiratory auscultation;
and details of any history of high blood pressure, type 2
diabetes mellitus or hypercholesterolemia), physical exam-
ination (axillary temperature, resting pulse, respiratory
rate, blood pressure measurements, oxygen saturation,
and auscultation abnormalities) and X-ray findings.
Sample size
The objective of the study is to demonstrate that penicil-
lin V is not inferior to amoxicillin. Considering a success
rate of 85% for the group treated with amoxicillin
[20,21] a total of 105 patients will be required in each
treatment group (total of 210) to detect a non-inferiority
margin of 15% at maximum between the two treatments
with a minimum power of 80% considering an alpha
error of 2.5% for a unilateral hypothesis and maximum
possible losses of 15%.
Statistical analyses
The intention-to-treat (ITT) population will include all
randomised patients receiving at least one dose of study
drug and the per-protocol (PP) population will include
patients receiving no systemic antimicrobial agents other
than the study drug for at least three days in the case of
clinical failure or ≥80% of study medication in the case
of cure, with adequate assessment of compliance and ab-
sence of major protocol violations.
To evaluate the comparability of the groups the two
groups will be analysed with variables expressed as
means and standard deviations for the case of quantita-
tive variables and with proportions in the case of quali-
tative variables. The variable of the principle result,
clinical cure, will be expressed as percentages and the
comparison of percentages in the two treatment groups
will be analysed using the Chi-square test. Logistic regres-
sion will be performed for the analysis of the predictive
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each of the variables analysed and multiadjustment for
each of the factors of the study with confidence intervals
of 95%. Variables with a p<0.20 on bivariant analysis will
be included in the analysis. A p value < 0.05 will be consid-
ered statistically significant.
Limitations and strengths
The main limitation of this study is that the microbio-
logical study is not taken into account. This study will
be carried out within the primary care setting in which
80% of community-acquired pneumonias are treated.
Bacterial eradication has been considered a secondary
outcome in many studies undertaken up to now. In a
recent review published by Gilbert this measure was not
recommended in mild-moderate pneumonia [22]. Des-
pite the use of aggressive tests such as serological analysis,
sputum samples, blood cultures, etc., to identify the causal
agent of pneumonia, the causative microorganism of the
pneumonia is only identified in 20% of ambulatory cases.
Moreover, primary care physicians judge the response to
treatment with eminently clinical but not with microbio-
logical criteria. Neither is the return to daily activities of
the patients considered because of the coexistence of vari-
ables which cannot be controlled and which cannot be
generalised to other countries. The percentage of referral
to hospital will not be taken into account since many
other confounding variables lay behind this variable in a
study of these characteristics. Neither will blood tests be
carried out. Although they may feasibly be done within
the primary care setting, they are not justified in this study
since this is not a study on safety.
This study will be undertaken in several health care
centres with an investigator-monitor figure in each. Pre-
vious meetings with the investigators and all the partici-
pating physicians of the different health care centres will
allow the homogeneity necessary to carry out the study.
Because penicillin is seldom used in our country and be-
cause such a high dose of penicillin is even less prescribed,
a Data and Safety Monitoring Board will be created, consti-
tuting a strength of the study. An independent group of ex-
perts will be responsible for monitoring patient safety and
treatment efficacy data during recruitment. From a micro-
biological standpoint, bacterial eradication is achieved
when the concentration of antibiotic is above 40-50% of
the time between β-lactams dose intervals. For partially re-
sistant strains, it is recommended that this time be above
60% [23]. We know that the bioavailability of penicillin V
is very variable, ranging from 25% and 60%. The concen-
tration of penicillin measured 1–3 hours after the last con-
sumption of a 250-mg penicillin V regimen taken four
times daily for 3–4 days is 0.1 - 2 μg/ml [23]. One study
found that the MIC achieved with penicillin V is higher
than with penicillin G administered parenterally [24]. In astudy carried out in Sweden, Fredlund et al. showed that
oral penicillin V is as effective as parenteral penicillin in
patients with community-acquired pneumonia when the
former is administered during ten days [25]. In the Scandi-
navian countries, where penicillin V is considered as the
first choice for uncomplicated pneumonia [1], high doses
ranging from 1 million to 1.5 million units thrice-daily are
recommended [26,27]. The dose of 1.6 million units has
been chosen in our study, since the percentage of inter-
mediate pneumococcal resistance strains is much greater
in Spain than in the Scandinavian countries. According to
data from the European Centre for Disease Prevention and
Control for the year 2011, intermediate pneumococcal re-
sistance to penicillin was 20.4% in Spain, 4.6% in Denmark,
3.4% in Norway and 0.3% in Sweden [28]. Regarding the
safety of the regimen of 1.6 million units (corresponding
approximately to 1 gram of penicillin V) thrice-daily, al-
though this dose is not marketed in our country, a presen-
tation of 1.5 million units is available in Scandinavian
countries. In addition, the British National Formulary rec-
ommends doses of up to 1 gram of penicillin V every 6 -
hours [29]. For this reason, we think that the dose of 1.6
million units taken thrice daily is fully justified in this clin-
ical trial.
Ethical aspects
The study will be conducted in accordance with the prin-
ciples of the Declaration of Helsinki, ICH Guidelines for
GCP and in full conformity with prevailing regulations.
The study has been approved by the Ethical Committee of
Investigation in Primary Care in Catalonia (Fundació
d’Investigació en Atenció Primària) (protocol code:
IJP–PEN-2012) (Additional file 1) and by the Agencia
Española del Medicamento y Productos Sanitarios. This
study does not require the use of unusual, additional tests:
only a chest X-ray will be undertaken to rule out a pneu-
monic process, being a test that is total justified in this
project. From an ethical point of view, this is to certify
that the objective of this study is important and relevant
for primary care, the power of the study may be consid-
ered as reasonable, this is an original study, the risks
which the participants may incur justify the investigation
being carried out with a totally favourable benefit/risk
quotient, and we ensure the external validity of the study
to the primary care reality, with the inclusion and exclu-
sion criteria described. Vulnerable populations will not be
participating in this study and neither will economic com-
pensation be given to patients for their participation. The
investigators will be free to publish the results of this
study, regardless of the results obtained.
The trial staff will ensure that the anonymity of the
participants is maintained. The participants will be iden-
tified only by a participant number on the consent re-
port form and an electronic database. All documents
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and authorized personnel. The study will comply with
the Data Protection Legislation which requires data to
be anonymised as soon as it is mandatory to do so.
Discussion
In this study, interventions and follow-ups will be simi-
lar to clinical practice. We believe that the methodology
used is very simple as it should be in primary care. The
data collection has been simplified to facilitate the inclu-
sion of cases in primary care offices. Chest x-ray is abso-
lutely necessary to confirm the diagnosis of pneumonia
and will therefore be an essential requisite for inclusion
of the patients to thereby avoid the inclusion of patients
who do not have the disease. Secondly, this study will
be undertaken in several health care centres with an
investigator-monitor figure in each. The antibiotics used
in this study have been in the Spanish pharmaceutical
market for more than 30 years, being amoxicillin the
first-drug of choice in our guidelines for the treatment
of pneumonia in the community setting in adults under
65 years [12,13]. Therefore, the principle of equipoise is
guaranteed in this clinical trial. Since the dose of penicil-
lin considered in this trial is high and infrequently used
in our country, a Safety Board will be the responsible
body to monitor the adverse events that might be
present during the development of the trial, thereby en-
suring the safety of the patients recruited. Only uncom-
plicated cases of pneumonia that could be treated in the
community will be taken into account. Even though pa-
tients with certain comorbidities such as high blood
pressure or type 2 diabetes mellitus might be included in
this trial we believe that the sample size and the
randomised, double-blind methodology used in this
study will eliminate a possible selection bias.
This study may have a socioeconomical impact. If treat-
ment with penicillin demonstrates to be as effective as that
of amoxicillin in uncomplicated community-acquired
pneumonia, this will have a considerable socioeconomic
impact. It may also have an impact on the treatment of
other respiratory tract infections. Most prescriptions of
amoxicillin and amoxicillin-clavulanate are prescribed for
respiratory tract infections [3]. If treatment of the most se-
vere respiratory infection (pneumonia) with penicillin is
found to be as effective as that with a broad-spectrum β-
lactam, this would aid in adopting a more rational use of
antibiotics in respiratory infections mainly caused by
pneumococci. Both the amount of antibiotics used and
how they are used contribute to the development of resist-
ance. The use of broad-spectrum antibiotics rather than
narrow-spectrum drugs is known to favour the emergence
of resistance by broadly eliminating competing susceptible
flora [30]. If the efficacy of penicillin is comparable to the
first-choice drug for this infection we will be able toencourage the use of narrower-spectrum antibiotics for
treating pneumococcal respiratory tract infections. On the
other hand, penicillin V is less expensive in our country
and this would therefore also aid in reducing drug costs
for the treatment of this infection.
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